Warfarin Sodium can cause major or fatal bleeding [see
Warnings and Precautions (5.1)
Perform regular monitoring of INR in all treated patients [see
Dosage and Administration (2.1)
Drugs, dietary changes, and other factors affect INR levels achieved with Warfarin Sodium therapy [see
Drug Interactions (7)
Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see
Patient Counseling Information (17)
JANTOVEN (Warfarin Sodium Tablets, USP) is an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors.
JANTOVEN (WARFARIN) is indicated for the following:
Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE).
Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.
Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
Limitations of Use
Warfarin Sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.
Media Articles Related to Jantoven (Warfarin)
New oral anticoagulants provide same stroke prevention as warfarin but cause less bleeding
Source: Stroke News From Medical News Today [2016.08.30]
The new oral anticoagulants provide the same stroke prevention as warfarin but cause less intracranial bleeding, reports an observational study in more than 43 000 patients presented at ESC...
Most patients taking warfarin long-term do not maintain stable INR values
Source: Stroke News From Medical News Today [2016.08.12]
In a study appearing in JAMA, Sean D. Pokorney, M.D., M.B.A., Eric D. Peterson, M.D., M.P.H., of Duke University Medical Center, Durham, N.C.
Herbal Supplements, Warfarin Can Be Hazardous Mix
Source: MedicineNet Saw Palmetto Specialty [2010.05.14]
Title: Herbal Supplements, Warfarin Can Be Hazardous Mix
Category: Health News
Created: 5/13/2010 4:10:00 PM
Last Editorial Review: 5/14/2010
Aspirin as effective as warfarin and safer in stroke prevention
Source: The Doctors Lounge - Neurology
Intracranial stenosis is caused by atherosclerosis - fatty deposits that build up on the inner walls of the arteries and restrict blood flow.
Results of trial into anticoagulants for cardioversion in atrial fibrillation patients published
Source: Stroke News From Medical News Today [2016.08.31]
Clinical trial finds edoxaban to be equally effective as current use of warfarin.
Published Studies Related to Jantoven (Warfarin)
Genetics and the clinical response to warfarin and edoxaban: findings from the
randomised, double-blind ENGAGE AF-TIMI 48 trial. 
anticoagulant rather than warfarin... INTERPRETATION: CYP2C9 and VKORC1 genotypes identify patients who are more likely
Relationship between time in therapeutic range and comparative treatment effect
of rivaroxaban and warfarin: results from the ROCKET AF trial. 
CONCLUSIONS: The treatment effect of rivaroxaban compared with warfarin for the
Outcomes of temporary interruption of rivaroxaban compared with warfarin in
patients with nonvalvular atrial fibrillation: results from the rivaroxaban once
daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for
prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). 
CONCLUSIONS: TI of oral anticoagulation is common and is associated with
Efficacy and safety of rivaroxaban compared with warfarin in patients with
peripheral artery disease and non-valvular atrial fibrillation: insights from
ROCKET AF. 
CONCLUSION: Patients with PAD in ROCKET AF did not have a statistically
Apixaban vs. warfarin with concomitant aspirin in patients with atrial
fibrillation: insights from the ARISTOTLE trial. 
CONCLUSION: Apixaban had similar beneficial effects on stroke or systemic
Clinical Trials Related to Jantoven (Warfarin)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN) [Recruiting]
The WARFARIN Study is a clinical trial designed to determine if the use of genetic
information related to warfarin sensitivity can help create a dose of warfarin that will
result in less hospitalizations and deaths related to warfarin.
Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects [Completed]
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the
pharmacokinetics (PK) of warfarin after single dose administration.
Pharmacogenetics of Warfarin Induction and Inhibition [Completed]
This research study will help determine how a person's genetic makeup affects their response
to drugs, the ability of the body to break down drugs, and their potential to experience an
interaction between drugs. The investigators are investigating the drug interactions with
the commonly used anticoagulant drug called warfarin. Warfarin is used for the treatment and
prevention of life-threatening abnormal blood clots such as deep vein thrombosis, heart
attacks, and strokes. The investigators chose warfarin for this study because it is a
commonly used drug and must be monitored closely to avoid side effects. The investigators
are interested in studying whether individuals with certain genetic profiles react
differently to warfarin when it is combined with other drugs. This research is being done to
see if certain genetic profiles require us to adjust warfarin doses differently than is
needed for the general population. Genetic profiles of subjects are determined from their
participation in the Pharmacogenetics Registry study (investigator Richard Brundage,
University of Minnesota).
The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the
warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive
Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin [Completed]
The purpose of this study is to determine whether DNA analysis improves the efficiency of
dosing and safety in patients who are being started on warfarin therapy. Warfarin, a blood
thinner (anticoagulant) prescribed to 1-2 million patients in the United States, is a
leading cause of drug-related adverse events (e. g., severe bleeding), in large part due to
dramatic (20-fold) differences between individuals in dose requirements. At least half of
this variability now can be explained by 3 common genetic variants, age, body size, and sex;
however, warfarin therapy continues to begin with the same dose in every patient with the
correct individual dose determined by trial and error. This study proposes to determine
genetic variations the same day from DNA simply obtained by swabbing the inside of the cheek
and use this information to determine the proper dose regimen individually in each patient.
The aim is to show that the investigators can achieve more rapid, efficient, and safe dosing
in up to 500-1000 individuals who are initiating warfarin therapy for various clotting
disorders across a large healthcare system in order to demonstrate improved dosing
effectiveness, efficiency, and safety with genetic-based dosing, which could lead to a
nationwide application resulting in as much as a $1 billion dollar annual benefit in
Genetic Response to Warfarin in Healthy Subjects [Completed]
The purpose of this study is to determine the importance of genetic differences on
individuals' response to warfarin in a group of healthy subjects. Warfarin is also known by
the "trade name" Coumadin and is in a class of medications called anticoagulants or "blood
thinners." Warfarin works by reducing the blood's ability to make clots. It is used to
stop blood clots from forming or growing larger in your blood and blood vessels. Warfarin
is prescribed for many conditions, including for people with certain types of irregular
heartbeat, people with replacement or mechanical heart valves, people who have suffered a
heart attack, people who have had orthopedic surgery, or who have a history of having blood
clots. Warfarin is used to prevent or treat deep vein thrombosis (swelling and blood clot
in a vein), pulmonary embolism (a blood clot in the lung), and strokes (a blood clot in the
brain). Researchers have found that certain genes may affect how a person's body will break
down or react to warfarin. If genetic information can help doctors better determine the
best dose of warfarin before it is first given, this may help the doctors get patients to
the correct levels of blood thinning and thereby reduce the risk of bleeding or the risk of
developing a blood clot. The expectation of this study is that this information will
ultimately improve warfarin therapy while lessening the risks associated with dosing errors.
This study is considered investigational because the subjects are healthy and not being
prescribed warfarin for clinical care.
Reports of Suspected Jantoven (Warfarin) Side Effects
Drug Interaction (2),
Status Epilepticus (2),
Drug Dose Omission (1),
Dizziness Postural (1),
Anticonvulsant Drug Level Below Therapeutic (1),
AGE-Related Macular Degeneration (1),
International Normalised Ratio Decreased (1),
Drug Administration Error (1),
Drug Level Decreased (1),
Blood Pressure Increased (1), more >>
Page last updated: 2016-08-31